Ocugen announced Q3 2024 financial results and secured $30 million in debt financing, extending its cash runway into Q1 2026. The company reported operating expenses of $14.4 million, including $8.1 million in R&D and $6.3 million in G&A expenses. Cash and restricted cash totaled $39.0 million as of September 30, 2024.The company's gene therapy programs showed significant progress, with OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa on track to complete enrollment in 1H2025. OCU410 has advanced to Phase 2 of the Phase 1/2 ArMaDa trial for geographic atrophy, while the DSMB approved enrollment for the second phase of OCU410ST's GARDian trial. The FDA also cleared the IND application for OCU200's Phase 1 trial.Health Canada approved OCU400 trial expansion to Canadian sites, potentially broadening commercialization opportunities. The FDA approved an Expanded Access Program for adult RP patients, targeting a combined market of 300,000 patients across the U.S., Canada, and Europe. New data from ongoing trials will be presented at an upcoming Clinical Showcase on November 12, 2024.

Ocugen announced Q3 2024 financial results and secured $30 million in debt financing, extending its cash runway into Q1 2026. The company reported operating expenses of $14.4 million, including $8.1 million in R&D and $6.3 million in G&A expenses. Cash and restricted cash totaled $39.0 million as of September 30, 2024.The company's gene therapy programs showed significant progress, with OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa on track to complete enrollment in 1H2025. OCU410 has advanced to Phase 2 of the Phase 1/2 ArMaDa trial for geographic atrophy, while the DSMB approved enrollment for the second phase of OCU410ST's GARDian trial. The FDA also cleared the IND application for OCU200's Phase 1 trial.Health Canada approved OCU400 trial expansion to Canadian sites, potentially broadening commercialization opportunities. The FDA approved an Expanded Access Program for adult RP patients, targeting a combined market of 300,000 patients across the U.S., Canada, and Europe. New data from ongoing trials will be presented at an upcoming Clinical Showcase on November 12, 2024.